XML 51 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
AGREEMENTS (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 14, 2016
Apr. 17, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Research and Development Expense, Total     $ 17,753 $ 8,481 $ 54,029 $ 17,200
Research and Development Arrangement [Member]            
Prepaid Expense, Current     1,400   1,400  
Maximum [Member] | Research and Development Arrangement [Member]            
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross   $ 14,200        
KarolinskaUniversityHospital [Member]            
Research and Development Expense, Total     700 0 302,017,000  
Payments For Clinical Trials Agreement         1,600  
Repayments To Be Made For Termination Of Licence Agreement $ 2,200          
Payments To Be Made For Other Related Agreements 2,600          
National Cancer Institute [Member]            
Research and Development Expense, Total         500  
Exclusive Patent License Agreement [Member]            
Payments For Upfront Licensing Fee         800  
Moffitt License Agreement [Member]            
Research and Development Expense, Total     2,000 0 4,300 400
Payments For Upfront Licensing Fee         100  
Cooperative Research and Development Agreement [Member]            
Research and Development Expense, Total     500   1,500  
PolyBioCept, AB - Exclusive and Co-Exclusive License Agreement [Member]            
Research and Development Expense, Total     $ 0   $ 200 $ 2,500
Payments For Upfront Licensing Fee       $ 2,400    
Payment For Upfront Exclusive License 2,500          
Additional Milesone Payable $ 8,700          
Number Of Unregistered Common Stock To Be Issued 2,219,376          
ReimbursementIn Relation To Transfer Of Knowhow $ 200          
Clinical Trials Management Fees Payable 100          
Consulting Fees Receivable $ 200          
Initial Term Of Licence Agreement 30 years